224 England | Full Member
Stevenage
Bioscience
Catalyst Stevenage BioScience Catalyst opened as the UK’s first open innovation biomedical
campus in 2012, and combines a unique blend of infrastructure and virtual networks
to drive collaboration. Backed by Government, GlaxoSmithKline, and Wellcome, the
remit is to catalyse innovation for patient benefit. SBC has a strong commitment to
companies that focus on high quality science and share its vision. Its development
of activity clusters and direct access to the expertise of major pharma are among its
unique characteristics. There is start-up and grow-on space for companies, plus a
commercially focused management team viewed as a leader in UK incubation.
L ocati on
Gunnels Wood Road
Stevenage
SG1 2FX
C ontact detai l s
Miranda Knaggs
Interim CEO
T: 01438 906906
E: [email protected]
www.stevenagecatalyst.com
The concept of SBC was born out of the
Government-identified need to better
translate academic innovation into
commercial reality in the healthcare
sector. From the outset, our vision was
to catalyse innovation by exploring new
ways of collaboration. This vision was
embraced and jointly funded by Wellcome,
GlaxoSmithKline, and Government. The
SBC Incubator opened in 2012 as the
UK’s first Open Innovation Campus,
bringing together academia, biotech and
pharmaceutical companies to advance
healthcare research more effectively.
In just five years we have incubated
more than 60 companies, which have
raised between them in excess of £220m
of investment, have a 95% tenant survival
rate, with 50% planning to expand in the
next 12 months. We have attracted inward
investment globally, including Japan,
Australia, USA, Belgium, Greece, and Italy.
innovation and impact
We have built our Incubator+ model and
its environment around a phenomenally
talented and dedicated team. This
UKSPA Directory 2017
includes the SBC Board, Management
and Operation Teams, GSK Consultancy
team Scinovo, the Experts Panel, the
>25 mentors and DiscoverAssist team,
all of whom have the resounding support
of our stakeholders.
Our unique focus on innovation
and impact has enabled us to build
a community of start-ups of which
more than 80% are IP-rich and research
intensive. These are the types of
companies that struggle to make it
through the valley of death of early
development, and require very specific
support and mentorship. SBC is designed
to provide that precise environment.
working with business
We are also home to novel academic
industry labs, and the world renowned
establishments of the University of
Cambridge and University College London
have set up a number of translational
projects at SBC.
As well as engaging with GSK, the
residence of the major corporate players
GE Healthcare, Lilly, Johnson & Johnson,
The GE Technology
Lab at the Stevenage
Bioscience Catalyst is
very well appointed